RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Gilead Sciences (NASDAQ:GILD) has agreed to invest $300M for a 49.9% stake in privately held Tizona Therapeutics.
GILD has the option to acquire the remainder of the South San Francisco-based cancer immunotherapy developer for $1.25B.
Tizona’s lead candidate is Phase 1-stage TTX-030, an anti-CD39 monoclonal antibody that it is co-developing with AbbVie for the treatment of solid tumors.
The company is selling 6.7M ADS’s consisting of an underwritten offering of 5M shares and a rights offering for the rest.
A selling shareholder will sell 750K ADS’s should the underwriters exercise their greenshoe option.
Pfizer (NYSE:PFE) has indicated interest in purchasing up to $200M worth of the new stock, which would work out to about 2.25M shares at the current price.
BNTX +8.6% – with today’s gains share are above their all-time closing high of $92.
Enzo Biochem (ENZ -0.6%) partners with Community Pharmacy Enhanced Services Network, to provide COVID-19 testing at 52 of the network’s 155 pharmacies across New York State.
The company will provide the full range of services, including reagent manufacturing capabilities, diagnostic instruments, and clinical laboratory services.
AbbVie (NYSE:ABBV) announces positive results from a Phase 3 clinical trial, Measure Up 2, evaluating Rinvoq (upadacitinib) in patients with moderate-to-severe atopic dermatitis (AD).
The study met all primary and secondary endpoints. The co-primary endpoints were the proportion of patients achieving EASI 75 (75% improvement in symptoms) and clear/almost clear skin at week 16 compared to placebo.
Detailed results will be submitted for presentation at a future medical conference and publication.
An earlier Phase 3, Measure Up 1, was also successful.
About a year ago, the FDA approved the JAK inhibitor for rheumatoid arthritis.
Nano cap Immuron Limited (NASDAQ:IMRN) jumps 118% premarket on robust volume in reaction to its announcement that IMM-124E, hyperimmune bovine antibodies used to make immune supplements Travelan and Protectyn, showed neutralizing activity against SARS-CoV-2 in cell-based assays.
Certain concentrations of IMM-124E inhibited viral replication by 90% with no signs of toxicity to cells.
CEO Jerry Kanellos, Ph.D. says the encouraging data warrants “further evaluation” for its potential use in COVID-19.
